this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.

Amendments

In the Specification:

At page 1, after the title and before the first line of text on page 1, please insert the following paragraph:

CROSS-REFERENCE TO RELATED APPLICATIONS

B1

This application is a U.S. National Phase of International Application No. PCT/EP98/04287, filed July 10, 1998, published in English as WO 99/02686 on January 21, 1999, and a continuation-in-part of U.S. Application No. 08/893,764, filed July 11, 1997, now U.S. Patent No. 6,172,211.

Substitute the paragraph beginning on page 49, line 14, with the following paragraph:

B2

One such fragment isolated and characterized here is the *tag 7* gene which exhibits a very high level of transcription in the liver-metastasizing VMR-L tumor (see Figure 2). Sequence analysis showed that the PCR fragment was flanked on both sides by the 5' terminal primer 5'-AATCGGGCTG-3' (SEQ ID NO:6). When the nucleotide sequence of a cDNA clone from the total VMR-L cDNA library was analyzed, a sequence which is homologous to this primer over a length of eight bp was found at a distance of 52

nucleotides from the 3' poly A+ tail of the cloned cDNA. It is likely that the traditional oligo-dT primer could be used in the "differential RNA display" technique instead of the 3' terminal primer, and only the 5' terminal primers could be varied; such an approach would probably decrease the number of fragments obtained, but would simultaneously increase the resolving capacity of the gel.

Substitute the paragraph beginning on page 56, line 24, with the following paragraph:

Differential display of mRNA was performed by the standard technique (Liang, P., and Pardee, A.B., *Science 257*:967-971 (1992)). Briefly, cDNA was obtained from 0.2 μg of mRNA by the reverse transcription reaction using the T12 AC primer (5'-TTTTTTTTTTTTAC-3') (SEQ ID NO:5) and Moloney Murine Leukemia Virus (M-MuLV) reverse transcriptase. T12AC and two short random 5' oligonucleotide primers (primer 1:5'-AATCGGGCTG-3' (SEQ ID NO:6); primer 2: 5'-AGTCAGCCAC-3' (SEQ ID NO:7)) were used as the 3' primers in two different combinations in the course of the polymerase chain reaction (PCR). Amplified cDNAs were separated by electrophoresis in 6% polyacrylamide gels containing 7 M urea.

Substitute the paragraph beginning on page 81, line 14, with the following paragraph:

One such fragment isolated and characterized here is the *tag7* gene which exhibits a very high level of transcription in the liver-metastasizing VMR-L tumor (see Figure 2). Sequence analysis showed that the PCR fragment was flanked on both sides by the 5' terminal primer 5'-AATCGGGCTG-3' (SEQ ID NO:6). When the nucleotide sequence of a cDNA clone from the total VMR-L cDNA library was analyzed, a sequence which is